Cargando…
Omalizumab for the treatment of severe allergic asthma in children: A tale of two
Omalizumab is a monoclonal antibody which targets immunoglobulin E. It is approved as an add‐on therapy for children with severe allergic asthma. Assessment of endotype and phenotype is necessary in order to correctly identify those patients who are most likely to respond to omalizumab. Children wit...
Autores principales: | Brannick, Sinéad, McDonald, Mary, Greally, Peter, Elnazir, Basil, Ahmareen, Oneza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393874/ https://www.ncbi.nlm.nih.gov/pubmed/36017116 http://dx.doi.org/10.1002/ccr3.6255 |
Ejemplares similares
-
Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018) -
Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience
por: Licari, Amelia, et al.
Publicado: (2017) -
Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children
por: Nishima, Sankei, et al.
Publicado: (2019) -
Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022) -
Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)